NovoCure Limited (NVCR) 10-Q 26 Oct 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Oct. 20, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-37565
Entity Registrant Name	NovoCure Limited
Entity Incorporation, State or Country Code	Y9
Entity Tax Identification Number	98-1057807
Entity Address, Address Line One	No. 4 The Forum
Entity Address, Address Line Two	Grenville Street
Entity Address, City or Town	St. Helier
Entity Address, Country	JE
Entity Address, Postal Zip Code	JE2 4UF
City Area Code	44 (0) 15
Local Phone Number	3475 6700
Title of 12(b) Security	Ordinary Shares, no par value
Trading Symbol	NVCR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		106,861,113
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001645113
Current Fiscal Year End Date	--12-31

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 154,860	$ 115,326
Short-term investments	766,388	854,099
Restricted cash	1,652	508
Trade receivables, net	65,133	86,261
Receivables and prepaid expenses	23,163	25,959
Inventories	36,806	29,376
Total current assets	1,048,002	1,111,529
LONG-TERM ASSETS:
Property and equipment, net	45,564	32,678
Field equipment, net	11,357	12,684
Right-of-use assets	29,014	23,596
Other long-term assets	12,416	11,161
Total long-term assets	98,351	80,119
TOTAL ASSETS	1,146,353	1,191,648
CURRENT LIABILITIES:
Trade payables	79,668	85,197
Other payables, lease liabilities and accrued expenses	77,493	73,580
Total current liabilities	157,161	158,777
LONG-TERM LIABILITIES:
Long-term debt, net	567,986	565,509
Deferred revenues	0	2,878
Long-term leases	22,054	18,762
Employee benefit liabilities	5,373	4,404
Other long-term liabilities	75	148
Total long-term liabilities	595,488	591,701
TOTAL LIABILITIES	752,649	750,478
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 106,748,270 shares and 105,049,411 shares at September 30, 2023 (unaudited) and December 31, 2022, respectively	0	0
Additional paid-in capital	1,334,120	1,222,063
Accumulated other comprehensive income (loss)	(1,992)	(2,433)
Retained earnings (accumulated deficit)	(938,424)	(778,460)
TOTAL SHAREHOLDERS' EQUITY	393,704	441,170
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 1,146,353	$ 1,191,648

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	106,748,270	105,049,411
Common stock, shares outstanding (in shares)	106,748,270	105,049,411

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 127,321	$ 130,998	$ 375,554	$ 409,411	$ 537,840
Cost of revenues	32,092	29,749	95,724	85,979	114,867
Gross profit	95,229	101,249	279,830	323,432	422,973
Operating costs and expenses:
Research, development and clinical studies	53,623	51,956	168,754	151,265	206,085
Sales and marketing	57,964	41,395	167,621	124,029	173,658
General and administrative	41,887	32,509	124,609	94,683	132,753
Total operating costs and expenses	153,474	125,860	460,984	369,977	512,496
Operating income (loss)	(58,245)	(24,611)	(181,154)	(46,545)	(89,523)
Financial income (expenses), net	10,023	1,194	27,948	(2,743)	7,677
Income (loss) before income tax	(48,222)	(23,417)	(153,206)	(49,288)	(81,846)
Income tax	1,263	3,159	6,758	5,943	10,688
Net income (loss)	$ (49,485)	$ (26,576)	$ (159,964)	$ (55,231)	$ (92,534)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.46)	$ (0.25)	$ (1.51)	$ (0.53)	$ (0.88)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.46)	$ (0.25)	$ (1.51)	$ (0.53)	$ (0.88)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	106,772,814	104,884,583	106,219,194	104,552,803	104,660,476
Weighted average number of ordinary shares used in computing diluted net income (loss) per share	106,772,814	104,884,583	106,219,194	104,552,803	104,660,476

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (49,485)	$ (26,576)	$ (159,964)	$ (55,231)	$ (92,534)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation adjustments	826	541	1,655	1,550	1,425
Unrealized gain (loss) from debt securities	15	(127)	440	(896)	(445)
Pension benefit plan	(852)	(625)	(1,654)	209	(244)
Total comprehensive income (loss)	$ (49,496)	$ (26,787)	$ (159,523)	$ (54,368)	$ (91,798)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Ordinary shares	Additional paid-in capital	Accumulated other comprehensive loss	Retained earnings (accumulated deficit)
Beginning balance (in shares) at Dec. 31, 2021		103,971,263
Beginning balance at Dec. 31, 2021	$ 410,494		$ 1,099,589	$ (3,169)	$ (685,926)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees	25,045		25,045
Exercise of options and vested RSUs (in shares)		587,825
Exercise of options and vested RSUs	3,148		3,148
Other comprehensive income (loss), net of tax benefit of $0	1,841			1,841
Net income (loss)	(4,647)				(4,647)
Ending balance (in shares) at Mar. 31, 2022		104,559,088
Ending balance at Mar. 31, 2022	435,881		1,127,782	(1,328)	(690,573)
Beginning balance (in shares) at Dec. 31, 2021		103,971,263
Beginning balance at Dec. 31, 2021	410,494		1,099,589	(3,169)	(685,926)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(55,231)
Ending balance (in shares) at Sep. 30, 2022		104,942,941
Ending balance at Sep. 30, 2022	445,401		1,188,864	(2,306)	(741,157)
Beginning balance (in shares) at Dec. 31, 2021		103,971,263
Beginning balance at Dec. 31, 2021	410,494		1,099,589	(3,169)	(685,926)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(92,534)
Ending balance (in shares) at Dec. 31, 2022		105,049,411
Ending balance at Dec. 31, 2022	441,170		1,222,063	(2,433)	(778,460)
Beginning balance (in shares) at Mar. 31, 2022		104,559,088
Beginning balance at Mar. 31, 2022	435,881		1,127,782	(1,328)	(690,573)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees	25,823		25,823
Proceeds from issuance of shares (in shares)		46,709
Proceeds from issuance of shares	2,759		2,759
Exercise of options and warrants and vested RSUs (in shares)		121,888
Exercise of options and vested RSUs	1,984		1,984
Other comprehensive income (loss), net of tax benefit of $0	(767)			(767)
Net income (loss)	(24,008)				(24,008)
Ending balance (in shares) at Jun. 30, 2022		104,727,685
Ending balance at Jun. 30, 2022	441,672		1,158,348	(2,095)	(714,581)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees	26,305		26,305
Exercise of options and warrants and vested RSUs (in shares)		215,256
Exercise of options and vested RSUs	4,211		4,211
Other comprehensive income (loss), net of tax benefit of $0	(211)			(211)
Net income (loss)	(26,576)				(26,576)
Ending balance (in shares) at Sep. 30, 2022		104,942,941
Ending balance at Sep. 30, 2022	445,401		1,188,864	(2,306)	(741,157)
Beginning balance (in shares) at Dec. 31, 2022		105,049,411
Beginning balance at Dec. 31, 2022	441,170		1,222,063	(2,433)	(778,460)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees	39,084		39,084
Exercise of options and vested RSUs (in shares)		1,137,751
Exercise of options and vested RSUs	5,211		5,211
Other comprehensive income (loss), net of tax benefit of $0	(258)			(258)
Net income (loss)	(53,061)				(53,061)
Ending balance (in shares) at Mar. 31, 2023		106,187,162
Ending balance at Mar. 31, 2023	432,146		1,266,358	(2,691)	(831,521)
Beginning balance (in shares) at Dec. 31, 2022		105,049,411
Beginning balance at Dec. 31, 2022	441,170		1,222,063	(2,433)	(778,460)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(159,964)
Ending balance (in shares) at Sep. 30, 2023		106,748,270
Ending balance at Sep. 30, 2023	393,704		1,334,120	(1,992)	(938,424)
Beginning balance (in shares) at Mar. 31, 2023		106,187,162
Beginning balance at Mar. 31, 2023	432,146		1,266,358	(2,691)	(831,521)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees	32,740		32,740
Proceeds from issuance of shares (in shares)		81,730
Proceeds from issuance of shares	2,883		2,883
Exercise of options and vested RSUs (in shares)		336,439
Exercise of options and vested RSUs	4,622		4,622
Other comprehensive income (loss), net of tax benefit of $0	710			710
Net income (loss)	(57,418)				(57,418)
Ending balance (in shares) at Jun. 30, 2023		106,605,331
Ending balance at Jun. 30, 2023	415,683		1,306,603	(1,981)	(888,939)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees	26,346		26,346
Exercise of options and vested RSUs (in shares)		142,939
Exercise of options and vested RSUs	1,171		1,171
Other comprehensive income (loss), net of tax benefit of $0	(11)			(11)
Net income (loss)	(49,485)				(49,485)
Ending balance (in shares) at Sep. 30, 2023		106,748,270
Ending balance at Sep. 30, 2023	$ 393,704		$ 1,334,120	$ (1,992)	$ (938,424)

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Other comprehensive income (loss), tax benefit	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ (49,485)	$ (26,576)	$ (159,964)	$ (55,231)	$ (92,534)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,803	2,659	8,246	7,924	10,624
Accrued Interest	480	1	530	(822)	(2,216)
Asset write-downs and impairment of field equipment	112	163	374	514	955
Share-based compensation	26,346	26,305	98,170	77,173	106,955
Foreign currency remeasurement loss (gain)	1,398	(141)	2,185	1,051	(3,256)
Decrease (increase) in accounts receivables	2,642	11,522	24,094	6,318	2,547
Amortization of discount (premium)	(6,691)	232	(15,822)	1,743	(1,536)
Decrease (increase) in inventories	(4,080)	2,952	(8,250)	(2,061)	(4,342)
Decrease (increase) in other long-term assets	3,971	1,665	3,585	5,885	7,107
Increase (decrease) in accounts payables and accrued expenses	6,265	5,265	(3,992)	(1,895)	14,257
Increase (decrease) in other long-term liabilities	(3,075)	(1,627)	(7,934)	(6,104)	(7,773)
Net cash provided by (used in) operating activities	(19,314)	22,420	(58,778)	34,495	30,788
Cash flows from investing activities:
Purchase of property, equipment and field equipment	(7,253)	(5,703)	(20,272)	(14,927)	(21,358)
Proceeds from maturity of short-term investments	275,549	358,729	916,433	1,074,763	1,179,289
Purchase of short-term investments	(251,038)	(503,270)	(810,513)	(1,071,733)	(1,297,888)
Net cash provided by (used in) investing activities	17,258	(150,244)	85,648	(11,897)	(139,957)
Cash flows from financing activities:
Proceeds from issuance of shares, net	0	0	2,883	2,759	5,224
Repayment of long-term debt	0	(7)	(10)	(21)	(28)
Exercise of options	1,171	4,211	11,004	9,343	10,295
Net cash provided by (used in) financing activities	1,171	4,204	13,877	12,081	15,491
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(97)	(107)	(69)	(252)	(97)
Increase (decrease) in cash, cash equivalents and restricted cash	(982)	(123,727)	40,678	34,427	(93,775)
Cash, cash equivalents and restricted cash at the beginning of the period	157,494	367,763	115,834	209,609	209,609
Cash, cash equivalents and restricted cash at the end of the period	156,512	244,036	156,512	244,036	115,834
Cash paid during the period for:
Income taxes paid (refunded), net	1,202	907	8,745	3,933	5,480
Interest paid	0	1	1	3	41
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	154,860	243,805	154,860	243,805	115,326
Restricted cash	1,652	231	1,652	231	508
Total cash, cash equivalents and restricted cash	156,512	244,036	156,512	244,036	115,834
Non-cash activities:
Right-of-use assets obtained in exchange for lease liabilities	$ 4,693	$ 2,828	$ 10,477	$ 6,687	$ 12,117

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and basis of presentation	ORGANIZATION AND BASIS OF PRESENTATION Organization . NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields ("TTFields") devices, including Optune and Optune Lua (collectively, our "Products"), for the treatment of solid tumor cancers. The Company markets Optune and Optune Lua in multiple countries around the globe with the majority of revenues coming from the use of Optune in the U.S., Germany and Japan. The Company also has a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market Optune in China, Hong Kong, Macau and Taiwan ("Greater China"). Financial statement preparation . The accompanying unaudited consolidated financial statements include the accounts of the Company and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the unaudited consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation for the periods presented. The preparation of these unaudited consolidated financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in these unaudited consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These unaudited consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the "2022 10-K") filed with the Securities and Exchange Commission on February 23, 2023. The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2022 10-K are applied consistently in these unaudited interim consolidated financial statements. Concentration Risks. The Company's cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally and the total value invested at any one institution is limited pursuant to the Company's investment policy. These investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand according to the terms of the securities. The Company's trade receivables are due from numerous governments and federal and state agencies that are paid from their respective budgets, and from hundreds of health insurance companies. The Company does not believe that there are significant default risks associated with these governments, agencies and health insurance companies based upon the Company's historical experience. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.

CASH, CASH EQUIVALENTS AND SHOR

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	9 Months Ended
	Sep. 30, 2023
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Cash, cash equivalents and short-term investments	CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash equivalents include items almost as liquid as cash, with maturity periods of three months or less when purchased, and short-term investments include items with maturity dates between three months and one year when purchased. As of September 30, 2023 and December 31, 2022, the Company’s cash and cash equivalents and short-term investments were composed of: September 30, 2023 Unaudited Fair value level Adjusted cost basis Unrealized gains Unrealized losses Fair market value Recorded basis Cash and cash equivalents Short-term investments (2) Cash $ 8,636 $ — $ — $ 8,636 $ 8,636 $ 8,636 $ — Money market funds Level 1 141,224 — — 141,224 141,224 141,224 — Certificate of deposits and term deposits Level 2 163,820 — — 163,820 163,820 5,000 158,820 HTM securities (1) U.S. Treasury bills Level 1 $ 109,595 $ 15 $ (14) 109,596 109,595 $ — $ 109,595 Government and governmental agencies Level 2 $ 24,596 $ — $ (15) 24,581 24,596 $ — $ 24,596 Corporate debt securities Level 2 $ 473,377 $ 83 $ (281) 473,179 473,377 $ — $ 473,377 $ 607,568 $ 98 $ (310) $ 607,356 $ 607,568 $ — $ 607,568 Total $ 921,248 $ 98 $ (310) $ 921,036 $ 921,248 $ 154,860 $ 766,388 December 31, 2022 Audited Fair value level Adjusted cost basis Unrealized gains Unrealized losses Fair market value Recorded basis Cash and cash equivalents Short-term investments Cash $ 9,697 $ — $ — $ 9,697 $ 9,697 $ 9,697 $ — Money market funds Level 1 105,629 — — 105,629 105,629 105,629 — Certificate of deposits and term deposits Level 2 316,946 — — 316,946 316,946 — 316,946 HTM securities (1) U.S. Treasury bills Level 1 $ 188,030 $ 8 $ (540) 187,498 188,030 $ — $ 188,030 Government and governmental agencies Level 2 $ 44,357 $ 12 $ (12) 44,357 44,357 $ — $ 44,357 Corporate debt securities Level 2 $ 304,766 $ 1,066 $ (587) 305,245 304,766 $ — $ 304,766 $ 537,153 $ 1,086 $ (1,139) $ 537,100 $ 537,153 $ — $ 537,153 Total $ 969,425 $ 1,086 $ (1,139) $ 969,372 $ 969,425 $ 115,326 $ 854,099 (1) Changes in fair value of held-to-maturity ("HTM") securities are presented for disclosure purposes as required by ASC 320 "Investments — Debt Securities" and are recorded as finance expenses only if the unrealized loss is identified as a credit loss. (2) Pursuant to a bank guaranty, $15,862 of short-term investments are pledged. See Note 4. In November 2022, the Company transferred all of its available-for-sale portfolio to HTM as part of the Company's investment strategy. Such transfers are made at fair value at the date of transfer. The net unrealized loss on these securities at the date of transfer was $911. These securities continue to be reported in accumulated comprehensive income (loss) and are amortized over the remaining lives of the securities as an adjustment to the yield. As of September 30, 2023 and December 31, 2022, the unamortized unrealized loss balances were $5 and $445, respectively, and are reported in accumulated other comprehensive income (loss). In accordance with ASC 820, "Fair Value Measurements and Disclosures," the Company measures its money market funds at fair value. The fair value of the money market funds and HTM securities, which is presented for disclosure purposes, is classified within Level 1 or Level 2. This is because these assets are valued using quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of September 30, 2023 and December 31, 2022, all investments mature in one year or less. Unrealized losses from debt securities are primarily attributable to changes in interest rates. The Company does not believe any remaining unrealized losses represent impairments based on the evaluation of available evidence.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories are stated at the lower of cost or net realizable value. The weighted average methodology is applied to determine cost. As of September 30, 2023 and December 31, 2022, the Company’s inventories were composed of: September 30, December 31, Unaudited Audited Raw materials $ 10,382 $ 4,314 Work in progress 7,518 9,321 Finished products 18,906 15,741 Total $ 36,806 $ 29,376

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	COMMITMENTS AND CONTINGENT LIABILITIES Operating Leases. The facilities of the Company are leased under various operating lease agreements for periods, including options for extensions, ending no later than 2044. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2026. Pledged deposits and bank guarantees. As of September 30, 2023 and December 31, 2022, the Company pledged bank deposits of $2,643 and $2,296, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained bank guarantees for the fulfillment of the Company’s lease and other contractual commitments of $2,991 and $2,459, respectively. In addition, €15,000 ($15,862) of the Company's short term investments are pledged to a bank as guarantee for the Company's due execution of cash concentration agreements. Senior secured revolving credit facility. On November 6, 2020, the Company entered into a three-year $150,000 senior secured revolving credit facility ("2020 Credit Facility") with a syndicate of relationship banks. On February 17, 2023, the Company gave irrevocable notice to the administrative agent under the 2020 Credit Facility that the Company terminated all commitments, effective February 22, 2023. This effectively terminated the 2020 Credit Facility, as the Company's ability to borrow and the Company's obligations to comply with all covenants ended on such date. The liens and guaranties in favor of the lenders are released. There was no early termination fee payable and the Company had no outstanding balance borrowed under the 2020 Credit Facility. The commitments under the 2020 Credit Facility were guaranteed by certain of the Company's subsidiaries and secured by a first lien on the Company's and certain of its subsidiaries’ assets. Outstanding loans bore interest per annum at a sliding scale based on a secured leverage ratio from 2.75% to 3.25% above the applicable interbank borrowing reference rate for the currency in which the loan is denominated. Additionally, the 2020 Credit Facility contained a fee for the unused revolving credit commitments at a sliding scale based on our secured leverage ratio from 0.35% to 0.45%. The 2020 Credit Facility contained financial covenants requiring maintenance of a minimum fixed charge coverage ratio and specifying a maximum senior secured net leverage ratio, as well as customary events of default which include a change of control, which are no longer applicable. Legal Proceedings. In June 2023, a putative class action lawsuit was filed against the Company, its Executive Chairman and its Chief Executive Officer. The complaint, which purports to be brought on behalf of a class of persons and/or entities who purchased or otherwise acquired ordinary shares of the Company from January 5, 2023 through June 5, 2023, allege material misstatements and/or omissions in the Company’s public statements with respect to the results from its phase 3 LUNAR clinical trial. The Company believes that the action is without merit and plans to defend the lawsuit vigorously. As of September 30, 2023, the Company has not accrued any amounts in respect of this claim, as it believes liability is not probable and the amount of any potential liability cannot be reasonably estimated.

CONVERTIBLE NOTE

CONVERTIBLE NOTE	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible note	CONVERTIBLE NOTE On November 5, 2020, the Company issued $575,000 aggregate principal amount of 0% Convertible Senior Notes due 2025 (the “Notes”). The Notes mature on November 1, 2025, unless earlier repurchased, redeemed or converted as set forth in the Notes. As of September 30, 2023, the conditions allowing holders of the Notes to convert were not met. The Notes are therefore not convertible as of September 30, 2023 and are classified as long-term liability. The net carrying amount of the liability of the Notes as of September 30, 2023 and December 31, 2022 are as follows: September 30, December 31, Unaudited Audited Liability component, net: Principal amount $ 575,000 $ 575,000 Unamortized issuance costs (7,014) (9,491) Net carrying amount of liability component (1) $ 567,986 $ 565,509 (1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820. The estimated fair value of the net carrying amount of liability component of the Notes as of September 30, 2023 and December 31, 2022 were $480,791 and $455,091, respectively. The net carrying amount of the liability is represented by the principal amount of the Notes, less total issuance costs plus any amortization of issuance costs. The total issuance costs upon issuance of the Notes were $16,561 and are amortized to interest expense using the effective interest rate method over the contractual term of the Notes. Interest expense is recognized at an annual effective interest rate of 0.59% over the contractual term of the Notes. Finance expense related to the Notes was as follows: Three months ended September 30, Nine months ended September 30, Year ended December 31, 2023 2022 2023 2022 Unaudited Unaudited Audited Amortization of debt issuance costs 836 831 2,477 2,461 3,293 Total finance expense recognized $ 836 $ 831 $ 2,477 $ 2,461 $ 3,293

SHARE OPTION PLANS AND ESPP

SHARE OPTION PLANS AND ESPP	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement, Recognized Amount [Abstract]
Share option plans and ESPP	SHARE OPTION PLANS AND ESPP In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). Under the 2015 Plan, the Company can issue various types of equity compensation awards such as share options, restricted shares, performance shares, restricted share units (“RSUs”), performance-based share units (“PSUs”), long-term cash awards and other share-based awards. Options granted under the 2015 Plan generally have a two-year or four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are canceled or forfeited before expiration become available for future grants. RSUs granted under the 2015 Plan generally vest over a three-year period. PSUs granted under the 2015 Plan generally vest between a three A summary of the status of the Company’s option plans as of September 30, 2023 and changes during the period then ended is presented below: Nine months ended September 30, 2023 Unaudited Number Weighted Outstanding at beginning of year 8,786,364 $ 37.27 Granted 942,643 66.90 Exercised (787,569) 13.94 Forfeited and canceled (321,556) 73.09 Outstanding as of September 30, 2023 8,619,882 $ 41.31 Exercisable options 6,810,232 $ 31.18 For the nine months ended September 30, 2023, options to purchase 787,569 ordinary shares were exercised, resulting in the issuance of 787,569 ordinary shares. A summary of the status of the Company’s RSUs and PSUs as of September 30, 2023 and changes during the period then ended is presented below. Nine months ended September 30, 2023 Unaudited Number Weighted Unvested at beginning of year 5,377,459 $ 66.87 Granted 1,457,681 70.39 Vested (829,560) 84.94 Forfeited and cancelled (178,399) 86.51 Unvested as of September 30, 2023 (1) 5,827,181 64.60 (1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of September 30, 2023, in accordance with ASC 718 "Compensation — Stock Compensation" as follows: September 30, 2023 Number of Fair value at grant date per PSU Total fair value at grant date 2,703,852 $ 48.16 $ 130,218 220,533 76.97 16,974 249,402 80.59 20,099 15,210 87.66 1,333 10,532 94.94 1,000 161,912 114.26 18,500 3,361,441 $ 188,127 These PSUs will be expensed over the performance period when the vesting conditions become probable in accordance with ASC 718. In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP are construed in a manner consistent with the requirements of such section. As of September 30, 2023, 4,787,003 ordinary shares were available to be purchased by eligible employees under the ESPP. The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions: Nine months ended September 30, Year ended December 31, 2023 2022 Unaudited Audited Stock Option Plans Expected term (years) 5.50-6.00 5.33-5.83 5.33-5.83 Expected volatility 63%-67% 60%-62% 60%-62% Risk-free interest rate 3.48%-4.16% 1.58%-3.04% 1.58%-4.23% Dividend yield 0.00 % 0.00 % 0.00 % ESPP Expected term (years) 0.50 0.50 0.50 Expected volatility 56%-122% 51%-77% 51%-77% Risk-free interest rate 4.76%-5.38% 0.19%-2.52% 0.19%-2.52% Dividend yield 0.00 % 0.00 % 0.00 % The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2023 and 2022, and the year ended December 31, 2022 was: Three months ended September 30, Nine months ended September 30, Year ended December 31, 2023 2022 2023 2022 Unaudited Unaudited Audited Cost of revenues $ 1,511 $ 1,013 $ 5,540 $ 2,994 $ 4,690 Research, development and clinical studies 6,683 7,430 26,999 21,855 30,790 Sales and marketing 8,973 7,686 30,830 21,143 28,826 General and administrative 9,179 10,176 34,801 31,181 42,649 Total share-based compensation expense $ 26,346 $ 26,305 $ 98,170 $ 77,173 $ 106,955

Basic and diluted net income (l

Basic and diluted net income (loss) per ordinary share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Basic and diluted net income (loss) per ordinary share	Basic and diluted net income (loss) per ordinary share Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares (deriving from options, RSUs, PSUs, convertible notes and the ESPP) considered outstanding during the period, in accordance with ASC 260-10 "Earnings Per Share", as determined under the if-converted method. The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share: Three months ended September 30, Nine months ended September 30, Year ended December 31, 2023 2022 2023 2022 Unaudited Unaudited Audited Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share $ (49,485) $ (26,576) $ (159,964) $ (55,231) $ (92,534) Weighted average number of ordinary shares used in computing diluted net income (loss) per share 106,772,814 104,884,583 106,219,194 104,552,803 104,660,476 Potentially anti-dilutive shares that were excluded from the computation of basic net income (loss) per share: Options 6,250,189 6,440,190 6,354,627 6,695,719 6,387,275 RSUs and PSUs 2,590,322 827,789 1,470,542 920,364 822,421 ESPP 96,444 21,462 150,930 52,601 62,910 Weighted anti-dilutive shares outstanding which were not included in the diluted calculation 8,936,955 7,289,441 7,976,099 7,668,684 7,272,606 Basic and diluted net income (loss) per ordinary share $ (0.46) $ (0.25) $ (1.51) $ (0.53) $ (0.88)

SUPPLEMENTAL INFORMATION

SUPPLEMENTAL INFORMATION	9 Months Ended
	Sep. 30, 2023
Geographic Areas, Long-Lived Assets [Abstract]
Supplemental information	SUPPLEMENTAL INFORMATION The Company operates in a single reportable segment. The following table presents long-lived assets by location: September 30, December 31, Unaudited Audited United States $ 38,482 $ 30,012 Israel 8,100 7,180 Switzerland 6,327 5,084 Japan 965 1,063 Germany 1,039 762 Others 2,008 1,261 Total long lived assets $ 56,921 $ 45,362 The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows: Three months ended September 30, Nine months ended September 30, Year ended December 31, 2023 2022 2023 2022 Unaudited Unaudited Audited United States $ 86,243 $ 102,651 $ 258,429 $ 308,270 $ 406,894 Germany 14,683 6,780 45,547 36,366 46,120 Japan 7,588 7,865 24,118 24,887 32,781 Greater China (1) 6,756 6,164 18,822 16,465 21,332 Others 12,051 7,538 28,638 23,423 30,713 Total net revenues $ 127,321 $ 130,998 $ 375,554 $ 409,411 $ 537,840 (1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2022 10-K.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Pay vs Performance Disclosure
Net income (loss)	$ (49,485)	$ (57,418)	$ (53,061)	$ (26,576)	$ (24,008)	$ (4,647)	$ (159,964)	$ (55,231)	$ (92,534)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023 shares
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	true
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Pritesh Shah [Member]
Trading Arrangements, by Individual
Name	Pritesh Shah
Title	Chief Growth Officer
Adoption Date	August 8, 2023
Arrangement Duration	1 year 23 days
Aggregate Available	103,304

CASH, CASH EQUIVALENTS AND SH_2

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2023
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Schedule of cash and cash equivalents	As of September 30, 2023 and December 31, 2022, the Company’s cash and cash equivalents and short-term investments were composed of: September 30, 2023 Unaudited Fair value level Adjusted cost basis Unrealized gains Unrealized losses Fair market value Recorded basis Cash and cash equivalents Short-term investments (2) Cash $ 8,636 $ — $ — $ 8,636 $ 8,636 $ 8,636 $ — Money market funds Level 1 141,224 — — 141,224 141,224 141,224 — Certificate of deposits and term deposits Level 2 163,820 — — 163,820 163,820 5,000 158,820 HTM securities (1) U.S. Treasury bills Level 1 $ 109,595 $ 15 $ (14) 109,596 109,595 $ — $ 109,595 Government and governmental agencies Level 2 $ 24,596 $ — $ (15) 24,581 24,596 $ — $ 24,596 Corporate debt securities Level 2 $ 473,377 $ 83 $ (281) 473,179 473,377 $ — $ 473,377 $ 607,568 $ 98 $ (310) $ 607,356 $ 607,568 $ — $ 607,568 Total $ 921,248 $ 98 $ (310) $ 921,036 $ 921,248 $ 154,860 $ 766,388 December 31, 2022 Audited Fair value level Adjusted cost basis Unrealized gains Unrealized losses Fair market value Recorded basis Cash and cash equivalents Short-term investments Cash $ 9,697 $ — $ — $ 9,697 $ 9,697 $ 9,697 $ — Money market funds Level 1 105,629 — — 105,629 105,629 105,629 — Certificate of deposits and term deposits Level 2 316,946 — — 316,946 316,946 — 316,946 HTM securities (1) U.S. Treasury bills Level 1 $ 188,030 $ 8 $ (540) 187,498 188,030 $ — $ 188,030 Government and governmental agencies Level 2 $ 44,357 $ 12 $ (12) 44,357 44,357 $ — $ 44,357 Corporate debt securities Level 2 $ 304,766 $ 1,066 $ (587) 305,245 304,766 $ — $ 304,766 $ 537,153 $ 1,086 $ (1,139) $ 537,100 $ 537,153 $ — $ 537,153 Total $ 969,425 $ 1,086 $ (1,139) $ 969,372 $ 969,425 $ 115,326 $ 854,099 (1) Changes in fair value of held-to-maturity ("HTM") securities are presented for disclosure purposes as required by ASC 320 "Investments — Debt Securities" and are recorded as finance expenses only if the unrealized loss is identified as a credit loss. (2) Pursuant to a bank guaranty, $15,862 of short-term investments are pledged. See Note 4.
Schedule of amortized cost and recorded basis of T-bills in short-term Investments	As of September 30, 2023 and December 31, 2022, the Company’s cash and cash equivalents and short-term investments were composed of: September 30, 2023 Unaudited Fair value level Adjusted cost basis Unrealized gains Unrealized losses Fair market value Recorded basis Cash and cash equivalents Short-term investments (2) Cash $ 8,636 $ — $ — $ 8,636 $ 8,636 $ 8,636 $ — Money market funds Level 1 141,224 — — 141,224 141,224 141,224 — Certificate of deposits and term deposits Level 2 163,820 — — 163,820 163,820 5,000 158,820 HTM securities (1) U.S. Treasury bills Level 1 $ 109,595 $ 15 $ (14) 109,596 109,595 $ — $ 109,595 Government and governmental agencies Level 2 $ 24,596 $ — $ (15) 24,581 24,596 $ — $ 24,596 Corporate debt securities Level 2 $ 473,377 $ 83 $ (281) 473,179 473,377 $ — $ 473,377 $ 607,568 $ 98 $ (310) $ 607,356 $ 607,568 $ — $ 607,568 Total $ 921,248 $ 98 $ (310) $ 921,036 $ 921,248 $ 154,860 $ 766,388 December 31, 2022 Audited Fair value level Adjusted cost basis Unrealized gains Unrealized losses Fair market value Recorded basis Cash and cash equivalents Short-term investments Cash $ 9,697 $ — $ — $ 9,697 $ 9,697 $ 9,697 $ — Money market funds Level 1 105,629 — — 105,629 105,629 105,629 — Certificate of deposits and term deposits Level 2 316,946 — — 316,946 316,946 — 316,946 HTM securities (1) U.S. Treasury bills Level 1 $ 188,030 $ 8 $ (540) 187,498 188,030 $ — $ 188,030 Government and governmental agencies Level 2 $ 44,357 $ 12 $ (12) 44,357 44,357 $ — $ 44,357 Corporate debt securities Level 2 $ 304,766 $ 1,066 $ (587) 305,245 304,766 $ — $ 304,766 $ 537,153 $ 1,086 $ (1,139) $ 537,100 $ 537,153 $ — $ 537,153 Total $ 969,425 $ 1,086 $ (1,139) $ 969,372 $ 969,425 $ 115,326 $ 854,099 (1) Changes in fair value of held-to-maturity ("HTM") securities are presented for disclosure purposes as required by ASC 320 "Investments — Debt Securities" and are recorded as finance expenses only if the unrealized loss is identified as a credit loss. (2) Pursuant to a bank guaranty, $15,862 of short-term investments are pledged. See Note 4.
Schedule of available-for-sale securities reconciliation	As of September 30, 2023 and December 31, 2022, the Company’s cash and cash equivalents and short-term investments were composed of: September 30, 2023 Unaudited Fair value level Adjusted cost basis Unrealized gains Unrealized losses Fair market value Recorded basis Cash and cash equivalents Short-term investments (2) Cash $ 8,636 $ — $ — $ 8,636 $ 8,636 $ 8,636 $ — Money market funds Level 1 141,224 — — 141,224 141,224 141,224 — Certificate of deposits and term deposits Level 2 163,820 — — 163,820 163,820 5,000 158,820 HTM securities (1) U.S. Treasury bills Level 1 $ 109,595 $ 15 $ (14) 109,596 109,595 $ — $ 109,595 Government and governmental agencies Level 2 $ 24,596 $ — $ (15) 24,581 24,596 $ — $ 24,596 Corporate debt securities Level 2 $ 473,377 $ 83 $ (281) 473,179 473,377 $ — $ 473,377 $ 607,568 $ 98 $ (310) $ 607,356 $ 607,568 $ — $ 607,568 Total $ 921,248 $ 98 $ (310) $ 921,036 $ 921,248 $ 154,860 $ 766,388 December 31, 2022 Audited Fair value level Adjusted cost basis Unrealized gains Unrealized losses Fair market value Recorded basis Cash and cash equivalents Short-term investments Cash $ 9,697 $ — $ — $ 9,697 $ 9,697 $ 9,697 $ — Money market funds Level 1 105,629 — — 105,629 105,629 105,629 — Certificate of deposits and term deposits Level 2 316,946 — — 316,946 316,946 — 316,946 HTM securities (1) U.S. Treasury bills Level 1 $ 188,030 $ 8 $ (540) 187,498 188,030 $ — $ 188,030 Government and governmental agencies Level 2 $ 44,357 $ 12 $ (12) 44,357 44,357 $ — $ 44,357 Corporate debt securities Level 2 $ 304,766 $ 1,066 $ (587) 305,245 304,766 $ — $ 304,766 $ 537,153 $ 1,086 $ (1,139) $ 537,100 $ 537,153 $ — $ 537,153 Total $ 969,425 $ 1,086 $ (1,139) $ 969,372 $ 969,425 $ 115,326 $ 854,099 (1) Changes in fair value of held-to-maturity ("HTM") securities are presented for disclosure purposes as required by ASC 320 "Investments — Debt Securities" and are recorded as finance expenses only if the unrealized loss is identified as a credit loss. (2) Pursuant to a bank guaranty, $15,862 of short-term investments are pledged. See Note 4.

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventories	As of September 30, 2023 and December 31, 2022, the Company’s inventories were composed of: September 30, December 31, Unaudited Audited Raw materials $ 10,382 $ 4,314 Work in progress 7,518 9,321 Finished products 18,906 15,741 Total $ 36,806 $ 29,376

CONVERTIBLE NOTE (Tables)

CONVERTIBLE NOTE (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Summary of the convertible notes	The net carrying amount of the liability of the Notes as of September 30, 2023 and December 31, 2022 are as follows: September 30, December 31, Unaudited Audited Liability component, net: Principal amount $ 575,000 $ 575,000 Unamortized issuance costs (7,014) (9,491) Net carrying amount of liability component (1) $ 567,986 $ 565,509 (1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820. The estimated fair value of the net carrying amount of liability component of the Notes as of September 30, 2023 and December 31, 2022 were $480,791 and $455,091, respectively. Finance expense related to the Notes was as follows: Three months ended September 30, Nine months ended September 30, Year ended December 31, 2023 2022 2023 2022 Unaudited Unaudited Audited Amortization of debt issuance costs 836 831 2,477 2,461 3,293 Total finance expense recognized $ 836 $ 831 $ 2,477 $ 2,461 $ 3,293

SHARE OPTION PLANS AND ESPP (Ta

SHARE OPTION PLANS AND ESPP (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement, Recognized Amount [Abstract]
Schedule of stock option plans	A summary of the status of the Company’s option plans as of September 30, 2023 and changes during the period then ended is presented below: Nine months ended September 30, 2023 Unaudited Number Weighted Outstanding at beginning of year 8,786,364 $ 37.27 Granted 942,643 66.90 Exercised (787,569) 13.94 Forfeited and canceled (321,556) 73.09 Outstanding as of September 30, 2023 8,619,882 $ 41.31 Exercisable options 6,810,232 $ 31.18
Schedule of RSUs and PSUs	A summary of the status of the Company’s RSUs and PSUs as of September 30, 2023 and changes during the period then ended is presented below. Nine months ended September 30, 2023 Unaudited Number Weighted Unvested at beginning of year 5,377,459 $ 66.87 Granted 1,457,681 70.39 Vested (829,560) 84.94 Forfeited and cancelled (178,399) 86.51 Unvested as of September 30, 2023 (1) 5,827,181 64.60 (1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of September 30, 2023, in accordance with ASC 718 "Compensation — Stock Compensation" as follows: September 30, 2023 Number of Fair value at grant date per PSU Total fair value at grant date 2,703,852 $ 48.16 $ 130,218 220,533 76.97 16,974 249,402 80.59 20,099 15,210 87.66 1,333 10,532 94.94 1,000 161,912 114.26 18,500 3,361,441 $ 188,127
Schedule of fair value assumptions used for All equity based awards estimated using black-scholes option pricing model	The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions: Nine months ended September 30, Year ended December 31, 2023 2022 Unaudited Audited Stock Option Plans Expected term (years) 5.50-6.00 5.33-5.83 5.33-5.83 Expected volatility 63%-67% 60%-62% 60%-62% Risk-free interest rate 3.48%-4.16% 1.58%-3.04% 1.58%-4.23% Dividend yield 0.00 % 0.00 % 0.00 % ESPP Expected term (years) 0.50 0.50 0.50 Expected volatility 56%-122% 51%-77% 51%-77% Risk-free interest rate 4.76%-5.38% 0.19%-2.52% 0.19%-2.52% Dividend yield 0.00 % 0.00 % 0.00 %
Schedule of non-cash share-based compensation expense related to company's equity-based awards	The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2023 and 2022, and the year ended December 31, 2022 was: Three months ended September 30, Nine months ended September 30, Year ended December 31, 2023 2022 2023 2022 Unaudited Unaudited Audited Cost of revenues $ 1,511 $ 1,013 $ 5,540 $ 2,994 $ 4,690 Research, development and clinical studies 6,683 7,430 26,999 21,855 30,790 Sales and marketing 8,973 7,686 30,830 21,143 28,826 General and administrative 9,179 10,176 34,801 31,181 42,649 Total share-based compensation expense $ 26,346 $ 26,305 $ 98,170 $ 77,173 $ 106,955

Basic and diluted net income _2

Basic and diluted net income (loss) per ordinary share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of basic and diluted net income (loss) per ordinary share	The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share: Three months ended September 30, Nine months ended September 30, Year ended December 31, 2023 2022 2023 2022 Unaudited Unaudited Audited Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share $ (49,485) $ (26,576) $ (159,964) $ (55,231) $ (92,534) Weighted average number of ordinary shares used in computing diluted net income (loss) per share 106,772,814 104,884,583 106,219,194 104,552,803 104,660,476 Potentially anti-dilutive shares that were excluded from the computation of basic net income (loss) per share: Options 6,250,189 6,440,190 6,354,627 6,695,719 6,387,275 RSUs and PSUs 2,590,322 827,789 1,470,542 920,364 822,421 ESPP 96,444 21,462 150,930 52,601 62,910 Weighted anti-dilutive shares outstanding which were not included in the diluted calculation 8,936,955 7,289,441 7,976,099 7,668,684 7,272,606 Basic and diluted net income (loss) per ordinary share $ (0.46) $ (0.25) $ (1.51) $ (0.53) $ (0.88)

SUPPLEMENTAL INFORMATION (Table

SUPPLEMENTAL INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2023
Geographic Areas, Long-Lived Assets [Abstract]
Schedule of long-lived assets by location	The following table presents long-lived assets by location: September 30, December 31, Unaudited Audited United States $ 38,482 $ 30,012 Israel 8,100 7,180 Switzerland 6,327 5,084 Japan 965 1,063 Germany 1,039 762 Others 2,008 1,261 Total long lived assets $ 56,921 $ 45,362
Schedule of revenues by geographic region	The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows: Three months ended September 30, Nine months ended September 30, Year ended December 31, 2023 2022 2023 2022 Unaudited Unaudited Audited United States $ 86,243 $ 102,651 $ 258,429 $ 308,270 $ 406,894 Germany 14,683 6,780 45,547 36,366 46,120 Japan 7,588 7,865 24,118 24,887 32,781 Greater China (1) 6,756 6,164 18,822 16,465 21,332 Others 12,051 7,538 28,638 23,423 30,713 Total net revenues $ 127,321 $ 130,998 $ 375,554 $ 409,411 $ 537,840 (1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2022 10-K.

CASH, CASH EQUIVALENTS AND SH_3

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Schedule of Cash and Cash Equivalents and Short-Term Investments (Details) € in Thousands, $ in Thousands	Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents	$ 154,860		$ 115,326	$ 243,805
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	607,568		537,153
Unrealized gains	98		1,086
Unrealized losses	(310)		(1,139)
Fair market value	607,356		537,100
Debt securities, available-for-sale and held-to-maturity, adjusted cost basis	921,248		969,425
Debt securities, available-for-sale and held-to-maturity, unrealized gains	98		1,086
Debt securities, available-for-sale and held-to-maturity, unrealized losses	(310)		(1,139)
Debt securities, available-for-sale and held-to-maturity, fair value	921,036		969,372
Debt securities, available-for-sale and held-to-maturity	921,248		969,425
Asset pledged as collateral
HTM Securities
Debt securities, available-for-sale and held-to-maturity, adjusted cost basis	15,862	€ 15,000
Level 1 | U.S. Treasury bills
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	109,595		188,030
Unrealized gains	15		8
Unrealized losses	(14)		(540)
Fair market value	109,596		187,498
Level 2 | Government and governmental agencies
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	24,596		44,357
Unrealized gains	0		12
Unrealized losses	(15)		(12)
Fair market value	24,581		44,357
Level 2 | Corporate debt securities
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	473,377		304,766
Unrealized gains	83		1,066
Unrealized losses	(281)		(587)
Fair market value	473,179		305,245
Cash and cash equivalents
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	0		0
Debt securities, available-for-sale and held-to-maturity	154,860		115,326
Cash and cash equivalents | Level 2 | Corporate debt securities
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	0		0
Short-term investments (2)
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	607,568		537,153
Debt securities, available-for-sale and held-to-maturity	766,388		854,099
Short-term investments (2) | Level 1 | U.S. Treasury bills
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	109,595		188,030
Short-term investments (2) | Level 2 | Government and governmental agencies
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	24,596		44,357
Short-term investments (2) | Level 2 | Corporate debt securities
HTM Securities
Debt securities, held-to-maturity, adjusted cost basis and recorded basis	473,377		304,766
Cash
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents, fair value	8,636		9,697
Cash | Cash and cash equivalents
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents	8,636		9,697
Money market funds | Level 1
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents, fair value	141,224		105,629
Money market funds | Cash and cash equivalents | Level 1
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents	141,224		105,629
Certificate of deposits and term deposits | Level 2
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents, fair value	163,820		316,946
Certificate of deposits and term deposits | Cash and cash equivalents | Level 2
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents	5,000		0
Certificate of deposits and term deposits | Short-term investments (2) | Level 2
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents	$ 158,820		$ 316,946

CASH, CASH EQUIVALENTS AND SH_4

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended
	Nov. 30, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Line Items]
Net unrealized loss on securities	$ 911
Cumulative impact to its accumulated deficit		$ 393,704	$ 415,683	$ 432,146	$ 441,170	$ 445,401	$ 441,672	$ 435,881	$ 410,494
AOCI, accumulated gain (loss), debt securities, available-for-sale, parent
Cash and Cash Equivalents [Line Items]
Cumulative impact to its accumulated deficit		$ 5			$ 445

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 10,382	$ 4,314
Work in progress	7,518	9,321
Finished products	18,906	15,741
Total	$ 36,806	$ 29,376

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Details) € in Thousands		9 Months Ended
	Nov. 06, 2020 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)	Dec. 31, 2022 USD ($)
Line of Credit Facility [Line Items]
Pledged bank deposits		$ 2,643,000		$ 2,296,000
Operating lease and other contractual commitments		2,991,000		2,459,000
Debt securities, available-for-sale and held-to-maturity, adjusted cost basis		921,248,000		$ 969,425,000
Asset pledged as collateral
Line of Credit Facility [Line Items]
Debt securities, available-for-sale and held-to-maturity, adjusted cost basis		15,862,000	€ 15,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Contractual term	3 years
Maximum borrowing capacity	$ 150,000,000
Early termination fee paid		0
Long-term debt		$ 0
Revolving Credit Facility | Minimum | Line of Credit
Line of Credit Facility [Line Items]
Basis spread on variable rate	2.75%
Fee for unused revolving credit commitments, percentage	0.35%
Revolving Credit Facility | Maximum | Line of Credit
Line of Credit Facility [Line Items]
Basis spread on variable rate	3.25%
Fee for unused revolving credit commitments, percentage	0.45%

CONVERTIBLE NOTE - Additional I

CONVERTIBLE NOTE - Additional Information (Details) - Convertible Debt - 0% Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	Sep. 30, 2023	Nov. 05, 2020
Debt Instrument [Line Items]
Aggregate principal amount		$ 575,000
Stated interest rate		0%
Debt issuance costs, gross	$ 16,561
Debt instrument, interest rate, effective percentage	0.59%

CONVERTIBLE NOTE - Liability an

CONVERTIBLE NOTE - Liability and Equity Components of the Convertible Notes (Details) - Convertible Debt - 0% Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal amount	$ 575,000	$ 575,000
Unamortized issuance costs	(7,014)	(9,491)
Net carrying amount of liability component	567,986	565,509
Estimated fair value	$ 480,791	$ 455,091

CONVERTIBLE NOTE - Amortization

CONVERTIBLE NOTE - Amortization of Finance Expense (Details) - 0% Convertible Senior Notes Due 2025 - Convertible Debt - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Debt Instrument [Line Items]
Amortization of debt issuance costs	$ 836	$ 831	$ 2,477	$ 2,461	$ 3,293
Total finance expense recognized	$ 836	$ 831	$ 2,477	$ 2,461	$ 3,293

SHARE OPTION PLANS AND ESPP - A

SHARE OPTION PLANS AND ESPP - Additional Information (Details)	9 Months Ended
	Sep. 30, 2023 shares
Share Capital [Line Items]
Options exercised (in shares)	787,569
ESPP
Share Capital [Line Items]
Ordinary shares available for grants (in shares)	4,787,003
Shares issued under plan (in shares)	787,569
2015 Plan
Share Capital [Line Items]
Ordinary shares available for grants (in shares)	18,729,954
2015 Plan | Options
Share Capital [Line Items]
Stock awards granted, expiration period (years)	10 years
2015 Plan | Options | Minimum
Share Capital [Line Items]
Stock awards granted, vesting period (years)	2 years
2015 Plan | Options | Maximum
Share Capital [Line Items]
Stock awards granted, vesting period (years)	4 years
2015 Plan | Restricted share units
Share Capital [Line Items]
Stock awards granted, vesting period (years)	3 years
2015 Plan | PSUs | Minimum
Share Capital [Line Items]
Stock awards granted, vesting period (years)	3 years
2015 Plan | PSUs | Maximum
Share Capital [Line Items]
Stock awards granted, vesting period (years)	6 years

SHARE OPTION PLANS AND ESPP - S

SHARE OPTION PLANS AND ESPP - Schedule of Stock Option Plan (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of options
Number of options, beginning outstanding (in shares) | shares	8,786,364
Number of options, granted (in shares) | shares	942,643
Number of options, exercised (in shares) | shares	(787,569)
Number of options, forfeited and canceled (in shares) | shares	(321,556)
Number of options, ending outstanding (in shares) | shares	8,619,882
Number of options, exercisable options (in shares) | shares	6,810,232
Weighted average exercise price
Weighted average exercise price, beginning outstanding (in usd per share) | $ / shares	$ 37.27
Weighted average exercise price, granted (in usd per share) | $ / shares	66.90
Weighted average exercise price, exercised (in usd per share) | $ / shares	13.94
Weighted average exercise price, forfeited and canceled (in usd per share) | $ / shares	73.09
Weighted average exercise price, ending outstanding (in usd per share) | $ / shares	41.31
Weighted average exercise price, exercisable options (in usd per share) | $ / shares	$ 31.18

SHARE OPTION PLANS AND ESPP -_2

SHARE OPTION PLANS AND ESPP - Schedule of RSUs and PSUs (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
RSUs and PSUs
Number of RSU/PSUs
Unvested at beginning of year (in shares)	5,377,459
Granted (in shares)	1,457,681
Vested (in shares)	(829,560)
Forfeited and cancelled (in shares)	(178,399)
Unvested at ending of year (in shares)	5,827,181
Weighted average grant date fair value
Unvested at beginning of year (in usd per share) | $ / shares	$ 66.87
Granted (in usd per share) | $ / shares	70.39
Vested (in usd per share) | $ / shares	84.94
Forfeited and cancelled (in usd per share) | $ / shares	86.51
Unvested at ending of year (in usd per share) | $ / shares	$ 64.60
PSUs
Weighted average grant date fair value
Number of PSUs (in shares)	3,361,441
Total fair value at grant date | $	$ 188,127
PSUs | Award One
Weighted average grant date fair value
Number of PSUs (in shares)	2,703,852
Fair value at grant date per PSU (in usd per share) | $ / shares	$ 48.16
Total fair value at grant date | $	$ 130,218
PSUs | Award Two
Weighted average grant date fair value
Number of PSUs (in shares)	220,533
Fair value at grant date per PSU (in usd per share) | $ / shares	$ 76.97
Total fair value at grant date | $	$ 16,974
PSUs | Award Three
Weighted average grant date fair value
Number of PSUs (in shares)	249,402
Fair value at grant date per PSU (in usd per share) | $ / shares	$ 80.59
Total fair value at grant date | $	$ 20,099
PSUs | Award Four
Weighted average grant date fair value
Number of PSUs (in shares)	15,210
Fair value at grant date per PSU (in usd per share) | $ / shares	$ 87.66
Total fair value at grant date | $	$ 1,333
PSUs | Award Five
Weighted average grant date fair value
Number of PSUs (in shares)	10,532
Fair value at grant date per PSU (in usd per share) | $ / shares	$ 94.94
Total fair value at grant date | $	$ 1,000
PSUs | Award Six
Weighted average grant date fair value
Number of PSUs (in shares)	161,912
Fair value at grant date per PSU (in usd per share) | $ / shares	$ 114.26
Total fair value at grant date | $	$ 18,500

SHARE OPTION PLANS AND ESPP -_3

SHARE OPTION PLANS AND ESPP - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 months	6 months	6 months
Expected volatility, minimum	56%	51%	51%
Expected volatility, maximum	122%	77%	77%
Risk-free interest rate, minimum	4.76%	0.19%	0.19%
Risk-free interest rate, maximum	5.38%	2.52%	2.52%
Dividend yield	0%	0%	0%
Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	63%	60%	60%
Expected volatility, maximum	67%	62%	62%
Risk-free interest rate, minimum	3.48%	1.58%	1.58%
Risk-free interest rate, maximum	4.16%	3.04%	4.23%
Dividend yield	0%	0%	0%
Stock Option Plans | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 6 months	5 years 3 months 29 days	5 years 3 months 29 days
Stock Option Plans | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years	5 years 9 months 29 days	5 years 9 months 29 days

SHARE OPTION PLANS AND ESPP -_4

SHARE OPTION PLANS AND ESPP - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 26,346	$ 26,305	$ 98,170	$ 77,173	$ 106,955
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	1,511	1,013	5,540	2,994	4,690
Research, development and clinical studies
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	6,683	7,430	26,999	21,855	30,790
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	8,973	7,686	30,830	21,143	28,826
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 9,179	$ 10,176	$ 34,801	$ 31,181	$ 42,649

Basic and diluted net income _3

Basic and diluted net income (loss) per ordinary share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss)	$ (49,485)	$ (57,418)	$ (53,061)	$ (26,576)	$ (24,008)	$ (4,647)	$ (159,964)	$ (55,231)	$ (92,534)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share	106,772,814		104,660,476	104,884,583			106,219,194	104,552,803	104,660,476
Potentially anti-dilutive shares that were excluded from the computation of basic net income (loss) per share:	8,936,955			7,289,441			7,976,099	7,668,684	7,272,606
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.46)			$ (0.25)			$ (1.51)	$ (0.53)	$ (0.88)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.46)			$ (0.25)			$ (1.51)	$ (0.53)	$ (0.88)
Stock Option Plans
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially anti-dilutive shares that were excluded from the computation of basic net income (loss) per share:	6,250,189			6,440,190			6,354,627	6,695,719	6,387,275
RSUs and PSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially anti-dilutive shares that were excluded from the computation of basic net income (loss) per share:	2,590,322			827,789			1,470,542	920,364	822,421
ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially anti-dilutive shares that were excluded from the computation of basic net income (loss) per share:	96,444			21,462			150,930	52,601	62,910

SUPPLEMENTAL INFORMATION - Sche

SUPPLEMENTAL INFORMATION - Schedule of Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	$ 56,921	$ 45,362
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	38,482	30,012
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	8,100	7,180
Switzerland
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	6,327	5,084
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	965	1,063
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	1,039	762
Others
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	$ 2,008	$ 1,261

SUPPLEMENTAL INFORMATION - Sc_2

SUPPLEMENTAL INFORMATION - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 127,321	$ 130,998	$ 375,554	$ 409,411	$ 537,840
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	86,243	102,651	258,429	308,270	406,894
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	14,683	6,780	45,547	36,366	46,120
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	7,588	7,865	24,118	24,887	32,781
Greater China
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	6,756	6,164	18,822	16,465	21,332
Others
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 12,051	$ 7,538	$ 28,638	$ 23,423	$ 30,713